Stockscreener 앱 받기
21.79
1.13%
-0.25
시장 영업 전:
22.04
0.25
+1.15%
전일 마감가:
$22.04
열려 있는:
$22.37
하루 거래량:
2.16M
Relative Volume:
0.78
시가총액:
$2.30B
수익:
$2.20B
순이익/손실:
$-842.79M
주가수익비율:
-2.5823
EPS:
-8.4382
순현금흐름:
$-332.39M
1주 성능:
+3.42%
1개월 성능:
-6.20%
6개월 성능:
+16.71%
1년 성능:
-65.77%
1일 변동 폭
$21.04
$22.66
1주일 범위
$20.30
$22.66
52주 변동 폭
$10.41
$63.92
사렙타 테라퓨틱스 Stock (SRPT) Company Profile
명칭
Sarepta Therapeutics Inc
전화
617-274-4000
주소
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
21.79 | 2.30B | 2.20B | -842.79M | -332.39M | -8.4382 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
사렙타 테라퓨틱스 Stock (SRPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Equal Weight |
| 2025-12-09 | 개시 | Wedbush | Outperform |
| 2025-11-05 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-09-22 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-29 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2025-07-29 | 개시 | Bernstein | Mkt Perform |
| 2025-07-29 | 재확인 | H.C. Wainwright | Sell |
| 2025-07-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2025-07-29 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-07-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-07-25 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-07-24 | 개시 | Citigroup | Sell |
| 2025-07-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2025-07-22 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-07-21 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-07-21 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2025-07-21 | 다운그레이드 | Needham | Hold → Underperform |
| 2025-07-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-07-18 | 다운그레이드 | Needham | Buy → Hold |
| 2025-06-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-06-17 | 개시 | Wolfe Research | Peer Perform |
| 2025-06-16 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-06-16 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | 다운그레이드 | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-04-11 | 개시 | Wells Fargo | Overweight |
| 2025-04-02 | 업그레이드 | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-11-27 | 재확인 | Needham | Buy |
| 2024-11-25 | 개시 | H.C. Wainwright | Sell |
| 2024-11-07 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | 개시 | Jefferies | Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-07-29 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-05-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-01-31 | 개시 | BMO Capital Markets | Outperform |
| 2023-12-13 | 재개 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-11-21 | 개시 | Wedbush | Outperform |
| 2023-10-31 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-04-26 | 개시 | SMBC Nikko | Outperform |
| 2023-04-04 | 개시 | Citigroup | Buy |
| 2023-03-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | 재확인 | BTIG Research | Buy |
| 2022-12-16 | 업그레이드 | UBS | Neutral → Buy |
| 2022-04-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-01-05 | 재확인 | Needham | Buy |
| 2021-12-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-05 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-09-15 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-08-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-01-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-01-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-01-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | 개시 | Berenberg | Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-20 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | 개시 | Mizuho | Buy |
| 2019-11-01 | 개시 | Guggenheim | Buy |
| 2019-08-21 | 재확인 | Needham | Buy |
| 2019-07-09 | 재확인 | Morgan Stanley | Overweight |
| 2019-07-01 | 재확인 | RBC Capital Mkts | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-11 | 재확인 | Credit Suisse | Outperform |
| 2018-10-12 | 개시 | Bernstein | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-26 | 재확인 | RBC Capital Mkts | Outperform |
| 2018-09-14 | 재개 | BofA/Merrill | Buy |
| 2018-09-06 | 개시 | Credit Suisse | Outperform |
| 2018-08-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | 재확인 | Robert W. Baird | Outperform |
| 2018-06-20 | 재확인 | Needham | Buy |
| 2018-06-19 | 재확인 | H.C. Wainwright | Buy |
모두보기
사렙타 테라퓨틱스 주식(SRPT)의 최신 뉴스
Sarepta, Amylyx and Neumora look ahead to key catalysts as Q1 earnings roll in - BioSpace
Sarepta Therapeutics Q1 2026 Earnings Preview — May 6, Street Expects $1.05 EPS - AlphaStreet
Are These 5 Biotech Stocks Set to Beat Q1 Earnings Estimates? - TradingView
Do Sarepta Therapeutics’ (SRPT) Bullish Earnings Forecasts and Vanguard Stake Hint at a Shifting Risk Profile? - Sahm
Sarepta (SRPT) Appoints New Acting Director for Biologics Evalua - GuruFocus
MSN Money - MSN
Vanguard Capital Management (NASDAQ: SRPT) reports 5.11% stake in Sarepta Therapeutics - Stock Titan
Sarepta Therapeutics (SRPT) price target decreased by 16.58% to 25.25 - MSN
Why is Sarepta Therapeutics (SRPT) up 24.2% since last earnings report? - MSN
Vanguard Portfolio Management (NASDAQ: SRPT) holds 6.75M shares (6.43%) - Stock Titan
Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Precision Trading with Sarepta Therapeutics Inc. (SRPT) Risk Zones - Stock Traders Daily
M&T Bank Corp Acquires Shares of 83,348 Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Therapeutics (SRPT) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Why Sarepta Therapeutics Stock Is Rising Nearly 5% Premarket - MSN
Sarepta Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Sarepta Therapeutics stock sinks further Tuesday, after halting shipment of bestselling drug Elvidys - MSN
Sarepta’s Elevidys to Remain on Market With New FDA Warning - MSN
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Navigating Biotech Volatility with Strategic Growth Potential - DirectorsTalk Interviews
Retail Bulls Stick With Sarepta After 8-Year-Old Patient’s Death Deemed Unrelated To DMD Gene Therapy - MSN
Sarepta Therapeutics Inc (HAM:AB3A) Stock Price, Trades & News - GuruFocus
Sarepta gains on data for muscular dystrophy therapies - MSN
Sarepta sells Arrowhead stock, activates $100M milestone payment - MSN
Sarepta to soon submit SNDAs for traditional approval for Duchenne treatments - msn.com
Sarepta cut to Underperform at BofA on Elevidys concerns - MSN
Sarepta to continue Elevidys shipments despite FDA request to halt - MSN
SRPT DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class ActionSRPT - TMX Newsfile
[ARS] Sarepta Therapeutics, Inc. SEC Filing - Stock Titan
Sarepta Therapeutics (NASDAQ: SRPT) outlines 2026 equity and ESPP plus CEO transition - Stock Titan
Sarepta Stock Slides Premarket After New FDA Warning Shrinks Market For Its $3.2M DMD Gene Therapy - MSN
Sarepta Loses Bid to Rehear Regenxbio DNA Patent Case Decision - Bloomberg Law News
Sarepta Therapeutics (SRPT) price target decreased by 10.97% to 22.48 - MSN
A Look At Sarepta Therapeutics (SRPT) Valuation After Recent Share Price Volatility - Yahoo Finance
Full Fed. Circ. Passes On Sarepta's Patent Rehearing Bid - Law360
OCGN's Gene-Agnostic Strategy Could Reset Retinal Therapy - TradingView
Sarepta Therapeutics to Announce First Quarter 2026 Financial Results - Business Wire
Sarepta Therapeutics, Inc. $SRPT Shares Purchased by Cwm LLC - MarketBeat
SRPT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Opinion: As Duchenne innovation booms, let’s ensure it becomes real progress - BioSpace
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment - TradingView
KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026? - TradingView
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Exploring the Future of RNA-Targeted Therapeutics with Promising Forward P/E - DirectorsTalk Interviews
A Look At Sarepta Therapeutics (SRPT) Valuation After Roche’s New Global Elevidys Phase 3 Trial - Sahm
Technical Reactions to SRPT Trends in Macro Strategies - Stock Traders Daily
Roche plots route to EMA approval for DMD gene therapy - BioWorld News
H.C. Wainwright reiterates Sarepta stock Sell rating at $5 target By Investing.com - Investing.com Canada
DNA Patent Eligibility Under Spotlight in Sarepta’s En Banc Bid - Bloomberg Law News
SRPT Reiterated by HC Wainwright & Co. -- Rating Maintained at S - GuruFocus
Sarepta/ Roche Duchenne therapy to face new late-stage trial targeting EU nod - MSN
HC Wainwright Reaffirms "Sell" Rating for Sarepta Therapeutics (NASDAQ:SRPT) - MarketBeat
사렙타 테라퓨틱스 (SRPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):